FDA Alerts

The FDA has broadened the approval of a non-small cell lung cancer drug, previously approved in 2014.

After successful testing, a new treatment for rheumatoid arthritis has been approved by the US Food and Drug Administration.

The FDA has approved the first drug specifically approved for the treatment of a type of vasculitis with previously limited treatment options.

The FDA has approved a new option for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

The US Food and Drug Administration has expanded the approval of a drug used to treat cystic fibrosis.

As an update to the safety alert issued last year, the FDA warns of a possible link to foot and leg amputation.

The FDA has posted a correction for this press release: "The notice posted to the Hematology/Oncology Approvals web page yesterday afternoon regarding an approval for the treatment of Hodgkin lymphoma...

The FDA approved the first anti-PD-1 therapy to be administered in combination with standard chemotherapy for the treatment of non-small cell lung cancer.

The FDA has approved a drug for the treatment of patients with with locally advanced or metastatic urothelial carcinoma.

The first combination pack for the treatment of advanced or metastatic breast cancer in postmenopausal women has been approved by the FDA.